In this video at ASCO 2018, James Mulshine, MD, discusses CMS coverage of low-dose CT lung cancer screening for selected Medicare beneficiaries, and clinical implications of early detection.
Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including recurrence, metastasis, and mortality.
Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.
Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival.
The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.
A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.
In the PROPHECY study, men with mCRPC and AR-V7–positive CTCs had only a 0% to 11% probability of benefit from abiraterone or enzalutamide.
In the ADORE trial, adjuvant FOLFOX in postoperative yp stage III rectal cancer significantly improved disease-free survival.
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
In this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.
USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course.